Melanoma trials in South Korea

In South Korea 12 Also abroad 578

12 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Where
Busan, Cheongju-si, Gyeonggi-do, Hwasun, Incheon, Seongnam-si, Seoul, Suwon
Age
18 years and over
People
340 worldwide
Run by
Inhibrx Biosciences, Inc
See details and how to joinNCT04198766
Phase 1Taking people
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Where
Seoul
Age
18 years and over
People
250 worldwide
Run by
Pfizer
See details and how to joinNCT07519655
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Seoul
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Daegu, Gyeonggi-do, Seongnam, Seoul
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Where
Seoul
Age
18 years and over
People
120 worldwide
Run by
AstraZeneca
See details and how to joinNCT07115043
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Daegu, Seoul
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 3Taking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Seongnam-si, Seoul
Age
18 years to 70 years
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
Phase 1/2Taking people
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Where
Seoul
Age
6 months to 17 years
People
370 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00
Phase 2Taking people
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Where
Busan, Daegu, Daejeon, Hwasun, Seongnam-si, Seoul
Age
19 years and over
People
45
Run by
Hanmi Pharmaceutical Company Limited
See details and how to joinNCT07449754
Phase 1/2Taking people
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Where
Seoul
Age
18 years and over
People
160 worldwide
Run by
CJ Bioscience, Inc.
See details and how to joinNCT05877430
Phase 1/2Taking people
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Where
Seoul, Suwon
Age
18 years and over
People
358 worldwide
Run by
GI Innovation, Inc.
See details and how to joinNCT05824975
Phase 1/2Taking people
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Where
Goyang-si, Seoul
Age
18 years and over
People
125
Run by
GeneMedicine Co., Ltd.
See details and how to joinNCT06265025